Information Links
Guidelines - Skin
Quick-reference summaries of key national treatment guidance for dermatological conditions including eczema and psoriasis.
NICE technology appraisals
Decisions by the National Institute for Health and Care Excellence on NHS access to treatments for dermatological conditions.
-
Ixekizumab for Treating Moderate to Severe Plaque Psoriasis (TA442)
-
Apremilast for Treating Moderate to Severe Plaque Psoriasis (TA419)
-
Nivolumab in Combination with Ipilimumab for Treating Advanced Melanoma (TA400)
-
Trametinib in Combination with Dabrafenib for Treating Unresectable or Metastatic Melanoma (TA396)
-
Adalimumab for Treating Moderate to Severe Hidradenitis Suppurativa (TA392)
-
Secukinumab for Treating Moderate to Severe Plaque Psoriasis (TA350)
-
Ustekinumab for the Treatment of Adults with Moderate to Severe Psoriasis (TA180)
-
Alitretinoin for the Treatment of Severe Chronic Hand Eczema (TA177)
-
Psoriasis, Treatment of Adults: Adalimumab (NICE)
-
Psoriasis in Adults: Infliximab (NICE)
MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.